MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Pacific Biosciences of California Inc

Затворен

СекторЗдравеопазване

2.21 -4.33

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.21

Максимум

2.39

Ключови измерители

By Trading Economics

Приходи

3.9M

-38M

Продажби

-1.3M

38M

Марж на печалбата

-98.853

Служители

575

EBITDA

3.2M

-32M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+2.13% upside

Дивиденти

By Dow Jones

Следващи печалби

12.02.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-66M

607M

Предишно отваряне

6.54

Предишно затваряне

2.21

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

Pacific Biosciences of California Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.01.2026 г., 23:29 ч. UTC

Горещи акции

Stocks to Watch: Atossa Therapeutics, Union Pacific

16.01.2026 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16.01.2026 г., 22:43 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16.01.2026 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16.01.2026 г., 21:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

16.01.2026 г., 21:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Auto & Transport Roundup: Market Talk

16.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

16.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

16.01.2026 г., 21:48 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16.01.2026 г., 21:41 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16.01.2026 г., 21:38 ч. UTC

Придобивния, сливания и поглъщания

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16.01.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16.01.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16.01.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16.01.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16.01.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16.01.2026 г., 20:44 ч. UTC

Печалби

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16.01.2026 г., 20:42 ч. UTC

Пазарно говорене

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16.01.2026 г., 20:28 ч. UTC

Пазарно говорене

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16.01.2026 г., 19:12 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16.01.2026 г., 18:53 ч. UTC

Пазарно говорене

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16.01.2026 г., 18:41 ч. UTC

Пазарно говорене

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16.01.2026 г., 18:31 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

16.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

16.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

16.01.2026 г., 17:03 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

16.01.2026 г., 17:03 ч. UTC

Пазарно говорене

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16.01.2026 г., 16:32 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16.01.2026 г., 16:20 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Pacific Biosciences of California Inc Прогноза

Ценова цел

By TipRanks

2.13% нагоре

12-месечна прогноза

Среден 2.4 USD  2.13%

Висок 3 USD

Нисък 2 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Pacific Biosciences of California Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

3

Купи

2

Задържане

0

Продай

Техническа оценка

By Trading Central

1.13 / N/AПодкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Weak Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat